IS THERE A DOCTOR IN THE HOUSE? USING FAILURE-TO-WARN LIABILITY TO ENHANCE THE SAFETY OF ONLINE PRESCRmING
CHESTER CIiuANO*
The ability to obtain prescription medications over the Internet witholll a proper prescription has inflamed regulators nationwide. Federal and state officials alike have proposed a host of new laws and regulations that attempt to limit this burgeoning phenomenon. Yet premature regulation of Internet prescribing cOllld prevent consumers from realizing the tremendous benefits the Internet might one day provide to the American health care delivery system. In this Note, Chester Chuang argues that subjecting Internet prescribing to a traditional failure-to-warn liability framework, rather than to additional regulations, adequately will ensure patient safety while allowing for the necessary innovations that will legitimize the distribution of prescription medications over the Internet. He suggests that pharmacetllical manufacturers can satisfy their duty to warn by contractually obligating websites that dispense prescription medications to implement comprehensive patient information systems. Chuang concludes that the proper application of this framework to these patient information systems will make certain that pharmacelllical mantlfacturen strike the proper balance between patients' health and safety concerns and the possibilities of Internet prescribing.

IN1'RODUCI10N
The learned intermediary doctrine exempts pharmaceutical companies from the general rule requiring manufacturers to warn consumers of dangers inherent in their products. 1 Under this doctrine, to fulfill its legal duty to warn, a prescription drug manufacturer need only provide adequate warnings about its medications to the prescribing physician, and not to the ultimate user.2 At its core, the doctrine is based on traditional notions of the ideal physician-patient relationship-the physician as a trusted father figure, and the deferential patient, confident in his care. The explosion of Internet prescribing, however, has forced a reevaluation of whether this traditional relationsbip is the only viable way to prescribe and dispense prescription medications. Prescription drugs are freely available on the World Wide Web, with or without a prescription, from sites with varying degrees of restrictions and reputability.3 In an online world where the physician is conspicuously absent, or at best virtual, the learned intermediary doctrine breaks down, leaving pharmaceutical manufacturers with the duty to warn the ultimate purchasers of the risks their medications carry.4 Because of the very nature of prescription drugs and the way they are distributed, however, most drug manufacturers are currently unable to provide adequate risk information directly to each patient. s Therefore, this duty effectively could preclude manufacturers from seIling their products online. 6 This Note argues that manufacturers can satisfy the duty to warn that is owed to consumers who purchase prescription medications from Internet prescribing sites by contractually obligating the websites to implement comprehensive patient information systems. Analyzing these systems under a traditional failure-to-warn liability framework will allow reputable sites to mature into reliable sources of prescription medications for consumers, while cutting off the supply of drugs to fraudulent sites without resorting to increased government regulation. Ideally, this framework \ViIl force manufacturers to weigh patients' health and safety with the commercial and practical advantages of Internet prescribing.
Part I of this Note chronicles the rise of Internet prescribing and the increased access to prescription medications it offers the everyday consumer. Part II outlines the learned intermediary doctrine and discusses why it is inapplicable to current online prescribing practices. This Part also describes the unique difficulties pharmaceutical manufacturers face when trying to implement a direct warning system, but manufacturer and the ultimate consumer"" (quoting AIm See infra Part n.c. 5 For further discussion, see infra Parts lLA, n.c. (Vol. 75:1452 concludes by arguing that these difficulties should not dissuade manufacturers from exploring online prescribing. Part m presents a solution for conveying adequate patient warnings directly to the patient, taking into account the unique challenges that Internet prescribing presents. This Part proposes that the application of a traditional failure-to-warn analysis will enable manufacturers to use the Internet to create comprehensive patient information systems that satisfy manufacturers' duty to warn in an online prescribing situation. There are two ways this might be accomplished: first, by enhancing the online physician-patient relationship so that it falls within the confines of the learned intermediary doctrine, or second, by implementing Individualized Patient Reports (IPRs) without increasing the physician's role in the transaction, thus spurning the protection of the learned intermediary doctrine completely. Fmally, this Part proposes that manufacturers, and not the government, must require web sites to implement either of these systems in order to ensure the success of these patient safety measures.
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I THE RISE OF INTERNET PRESCRIBING
Within the last few years, a multitude of pharmaceutical sites have emerged on the Internet, selling everything from prescription and over-the-counter medications to health and beauty aids.' The exploding popularity of these sites is closely linked to the development of three new, increasingly popular, "lifestyle" medications designed to enhance quality of life rather than to cure disease: Viagra, for impotence; Propecia, for hair loss; and Xenical, for weight loss.8 Often, patients who wish to take these medications are embarrassed to ask their doctors for a prescription and find comfort in the privacy and the anonymity afforded them by ordering online. 9 The allure of these sites is so strong that some experts predict that in the next five years 7 See Robin Herman, Drugstore on the Net (It's Quick, It's Convenient and It's Unregulated. Consumers Run the Risk of Harm With Do-It-Yourself Prescriptions), Wash. Post, May 4, 1999, at Z14 ("In the past year, hundreds of pharmaceutical sites have popped up on the Internet •..• "). 8 See Naftali Bendavid, Prescriptions via Internet Pose Dangers: Doctors Fear Patients Will Skip Supervision, Checkups, Chi. 1li.b., June 16, 1999, § 1, at 1; Sberyl Gay Stolberg, On-Line Prescription Practices Create Headache for Regulators, Chi. nib., June 27, 1999, § 1. at 8 (noting that online prescdbing is tied to emergence of Viagra, Propecia, and Xenical). 9 See, e.g., Bendavid, supra note 8, § 1, at 1 (noting that Internet is attractive to "those who may be embarrassed to admit, even to their doctor, that they are impotent or concerned about their baldness or weight").
online sales for prescription drugs and health and beauty products may exceed $6 billion. tO These websites fall roughly into two categories: "pharmacybased" and "prescribing-based."l1 "Pharmacy-based" sites operate much like traditional comer drugstores. They are state-licensed and require an off-site doctor's prescription before they will dispense medications. 12 These sites are regulated under conventional food and drug Iaws,13 and will thus not be the focus of this Note. "Prescribingbased" sites, on the other hand, circumvent the traditional models of prescription drug distribution. These types of sites further can be categorized as either Online Consultation or International Freelance sites. Online Consultation sites require customers to complete a brief medical questionnaire online, usually involving general physical information and details of concomitant medication use, which is then reviewed by the site's physician, who issues the prescription for the requested drug. t4 The medication is then shipped directly by the site to the consumer.IS Usually, little information is available about the physician's qualifications, with some sites disclosing only that their 10 See Sarah A Webster, Internet Drug Sales Investigated: Critics Raise Wamiog About Health Risks of Online Prescriptions, Detroit News, JUDe 7,1999, at AI, available in 1999 WL 3927805.
11 See Sbari Roan, Your Friendly Neigh~orhood E·Drugstore: lbe New Online Pharmacies Offer Prompt. Hassle-Free Service, but Health Experts Worry lbat the Sites Also Pose Serious Potential for Misuse, LA. 11Dles, Sept 20, 1999, at SI (differentiating between "pbarmacy-based" and "prescribing-based" sites). 13 See Roan. supra note 11, at SI (writing that pharmacy·based sites are "legitimate [and] state-licensed"). Pharmacy-based sites require paticnts to send prescriptions to the website or will contact directly patients' doctors for prescriptions bcfore dispeosiog medication, much like mail-order pharmacies. They are regulated under the existing Jaws and regulations for mail-order pharmacies. See generally Gregory S. Munro This Note also will not focus on the direct liability of the prescribing-based sites themselves. Though injured plaintiffs likely will sue both the website and the manufacturer, it is assumed that most plaintiffs will focus primarily on the manufacturers' liability due to their greater financial resources. For a more thorough explanation of this so-called "deep pock. 19 See Herman, supra note 7, at Z14 (observing that virtual pbarmacies offer "consumers the option of making purchases at any time without having to leave home ••• [and] ship products directly from central distributors to customers, avoiding the overhead costs of a real storefront"); Roan, supra note 11, at Sl (noting that "online pharmacies hope to lower overhead costs and pass on lower prices to consumers").
to physicians and pharmacists, however, such sites may expose consumers to possible adverse drug reactions and other health risks.20
The recent explosion of prescribing-based sites has state and federal authorities grappling with difficult enforcement issues. At the federal level, the reaction has been one of bewilderment Although it is usually a violation of the Food, Drug and Cosmetic Act for Americans to order medications from a foreign country ,21 the law is extremely difficult to enforce. 22 In fact, Americans have been buying drugs illegally from overseas mail-order catalogs for years, albeit in much more limited numbers.23 Recently, Representative Ron Klink introduced a bill that would require all online pharmacies to post identifying information about their doctors, pharmacists, and office addresses. 24 President Clinton also has proposed legislation requiring 20 See Bendavid, supra note 8, § 1, at 1 (noting that there is "DO way of knO\\ing if the patient is answering the questions truthfully, or if a physical examination would reveal a more serious condition"); Herman, supra note 7, at Z14 ("Critics worry that without a face· to-face meeting with a doctor, customers can easily lie about their age and health status in order to get the regulated products they want •••• "); Roan, supra Dote 11. at SI (indicating that American Medical Association believes that "risks in using these prescribing sites are overwhelming"); Webster, supra note 10, at A1 (writing that federal and state officials are "worried about the health risks to people ordering drugs without a doctor's visit or a pbar~ macist's review of potential drug interactions"); see also Bloom & Ianuacone, supra Dote 14, at 833 (arguing that giving incorrect or false information to obtain prescription from one of these sites was "indirectly facilitated by preselected click~(f choices a .. '3i1able to the purchaser"). 21 In a piecemeal attempt to regulate these sites, a few states have taken action. Illinois passed a law requiring any Internet site that ships to a patient in the state to have an Illinois pharmacy license;32 Nevada's Board of Medical Examiners barred its doctors from making Internet sales unless they actually see the patient;33 medical boards in WISconsin and Colorado have disciplined doctors who prescribed medications to patients they never examined;34 and other states currently are investigating these sites. 35 Enforcement is confounded, however, by the fact that few of these sites reveal their geographic location, let alone specific identifying information about their physicians. 36 In fact, very few doctors or pharmacists have been sanctioned for Internet prescribing. 37
The private sector has also moved to address this thorny issue. The American Medical Association (AMA) has approved a resolution aimed at discouraging doctors from writing prescriptions through an Internet consultation. 38 Pfizer Inc., the maker of Viagra, has filed a complaint with the FTC seeking to stop the prescribing of Viagra without adequate safeguards. Pfizer complains that the online questionnaires used by prescribing-based sites do not adequately convey the risks of concomitant use of nitrates, and fail to discover underlying medical problems that remain undiagnosed because of the lack of a 31 See Senate Testimony, supra note 28 ("[M]ost drug sales websites are actually made up of multiple related sites and links, thereby making investigations much more complex and resource intensive."); Bendavid, supra note 8, § 1, at 1 (noting that state medical and pharmacy boards are "poorly equipped to deal with cyberspace, where a patient in one state can order pills from a druggist in another state, with the prescription often written by a doctor in a third" 38 See American Medical Association Resolution 832, Guidelines for Medical Practice Through the Internet (visited July 8, 2000) <http://www.ama-assn.orgfmeetingsipublicJannual99/reportslonsitelrtflh832.rtf> (stating that "physician[s] should refrain from writing prescriptions for medication resulting only from a sale or consultation over the intemet"); Cohen, supra note 27, at 1 (discussing shortcomings of formal regulation). physical exam. 3~ Pfizer has also contacted all state medical boards, asking them to remind doctors that it is improper to prescribe Viagra without examining the patient. 40 Drug manufacturers like Pfizer are right to be deeply concerned about the inadequate safeguards implemented by prescribing-based sites, since they will not be able to plead ignorance of these inadequacies if sued. By law, manufacturers are "presumed to possess an expert's knowledge of the arts, materials, and processes of the pharmaceutical business."41 This knowledge includes a familiarity with the distribution and administration of their products. 42 Though obtaining prescription medication through foreign-based websites might be illegal, a line of cases holds that manufacturers must anticipate all reasonably foreseeable uses and misuses of their products. 43 ]laintiff can cite no authority (and we can find none) under either New Jersey or New York law which supports the existence of a duty to warn middlemen that consumers. after purchasing their products, may alter the products and harm third parties."); Gaines-'Thbb v. ICI Explosives, USA, Inc., 160 F.3d 613, 625 (10th Cir. 1998) ("[D]ercndants bad no duty to warn the suppUers of its product of possible criminal misuse. ").
It is beyond the scope of this Note to determine whether a court indeed would decide whether ordering a prescription drug from an International Freelance site was reasonably foreseeable and thus apply failure-ta-warn liability. In fact. a court in such a situation may hold the plaintiff contributorily negligenL Suffice it to say that it is unchartcd territory IlDd the very possibility of such lawsuits should spur manufacturers to take heed.
for the government to take action to regulate these sites. 44 Even if federal and state regulations were successful in inhibiting United States~based Online Consultation sites, foreign~based Online Consultation sites and International Freelance sites hardly would be affected. 4s Internet prescribing in its current state presents the courts with a scenario beyond the reach of the learned intermediary doctrine. With no discernible learned intermediary to rely upon, the courts will be forced to assign the duty to warn the patient to manufacturers, leaving them open to tremendous liability unless effective warnJngs are provided. 46 44 Government regulations may not be the most effective way to police this burgeoning phenomenon. RegUlations will be unable to reach International Freelance websites. Sec Drugstores on the Net, supra note 26, at 99 (statement of Janet Woodcock) ("The most difficult problem to address is the online sale of drugs to U.S. residents by sellers in foreign countries."); Bendavid, supra note 25, at N1 ("There is at least one large group that for now will remain beyond the reach of regulators: foreign Web sites."); Pent, supra note 25, at Al (same). 
A. The Learned Intermediary Rille
The learned intermediary rule limits a prescription drug manufacturer's duty to warn to "an obligation to advise the prescribing physician of any potential dangers that may result from the drug's use. "47 By warning the doctor, the manufacturer relieves itself of any duty to warn the users of its products directly.48 As the Fifth Circuit explained:
Prescription drugs are likely to be complex medicines. esoteric in formula and varied in effect. As a medical e"l'ert, the prescribing physician can take into account the propensities of the drug, as well as the susceptibilities of his patient. His is the task of weighing the benefits of any medication against its potential dangers. The choice he makes is an informed one, an individualized medical judgment bottomed on a knowledge of both patient and palliative. 49 Proponents of the learned intermediary rule stress that it is based on "a desire not to intrude upon or disturb the well-established doctorpatient relationship. "SO Therefore, a physician, using her individualized medical judgment, should be entrusted ,vith selecting the correct medication for each patient and specifically tailoring the warnings to him or her. Furthermore, courts have assumed that detailed side-effect information would in fact deter patients from taking the medication at all, despite their physician's best judgment. S1 Advocates of the 41 rule also argue that it would be extremely difficult to fashion written warnings that are easily understood by lay people, yet sufficiently comprehensive to cover all of the possible side-effects, which are "inherently varied, complex, and dependent upon an individual patient's susceptibilities."S2 Even if devising an adequate warning were possible, pharmaceutical manufacturers must further ensure that it would reach patients who often neither receive the drug in its original packaging nor have any significant direct contact with the manufacturer. 53 
B. The Learned Intermediary Rule Revisited
The learned intermediary rule is premised on traditional conceptions of the ideal physician-patient relationship-a relationship that has been eroded heavily by the realities of our modern health care system. Today's managed care organizations often prevent patients from establishing long term relationships with physicians and usually provide patients with shorter consultations. best for the patient. n). But see Walsh et at. supra note 52, at ff/7 n.211 ("rrJhere will be attempts to defeat the learned intermediiU)' doctrine ••• because the physician no longer has the freedom to prescribe what is best for the patient •••• l.N]otwithstanding the restrictions these plans place on physician autonomy. the doctor's independent medical judgement should be sufficient to defeat such daims.").
58 See Noah, supra note 51, at 161 ("[110 date no jurisdiction has completely abandoned the learned intermediary rule •••• n). There are Umited exceptions to the learned intermediary rule. Some courts have held it inapplicable at mass immunization clinics. scription drugs serve an essential role in the health of our society and because in most cases existing physician-patient relationships can still provide more effective warnings than the manufacturer can give,S9 arguably, without the protection of the learned intermediary rule, manufacturers simply would cease to produce prescription medications because the duty to warn consumers directly would be too onerous a burden for them to sustain. 60 In sum, the learned intermediary rule See, e.g., Reyes v. Wyeth Lab., Inc., 498 F.2d 1264, 1277 (5th Cir. 1974) (stating that vac· cine is "dispensed without the sort of individualized medical balancing of the risks to the vaccinee that is contemplated by the prescription drug exception"); Davis v. Wyeth Lab., Inc., 399 F.2d 121, 131 (9th Cir. 1968) (noting that "although the drug was denominated a prescription drug it was not dispensed as such"). These cases have been reversed to some extent by the National Childhood Vaccine Injury Act of 1986, 42 U.S.C. § § •• belies each of the premises on which the learned intermediary doctrine rests" and concluded that pharmaceutical manufactUrers who utilize direct·to-consumer advertisements also must provide adequate warnings to the consumer within those advertisements. ld. at 1256-57. Courts continue to disagree over whether the learned intermediary rule should be applicable in the face of direct·to-consumer advertising; indeed, the New Jersey Supreme Court acknowledged that its decision was in direct conflict with a contemporaneous one by the Fifth Circuit. See id. . 59 This will be discussed further, see infra Part ItC.l.a. 60 See Harrison, 165 F.3d at 379 ("Our understanding of the rationale of the learned intermediary doctrine, at least in substantial part, is that it seeks to encourage the drug manufacturer to make available prescription drugs despite potentially harmful side ef- might be viewed as a rough judicial compromise between the commercial interests of the manufacturers, the practical advantages of the wide availability of prescription medications, and the health and safety of patients.
Courts facing Internet prescribing-related injury claims, however, will find it difficult to apply the learned intermediary rule." It is widely recognized that the learned intermediary rule should not apply when drugs are dispensed in the absence of a health care provider. 6z Prescribing-based sites fall squarely within such a situation. In the best case scenario, a prescription drug is mailed directly to the patient's home on the basis of the patient's answers to a brief online questionnaire that supposedly was reviewed by an unseen physician. At worst, using an International Freelance site, the patient orders the medication without even going through the pretense of an online consultation and without ever obtaining a prescription. It is doubtful that even at an Online Consultation site, any health care professional balances the risks and the benefits of specific medications for individual patients as originally envisioned by the learned intermediary rule. As a result, manufacturers are left with the duty to provide risk information directly to any patient that obtains their medications in this fashion.
C. Conveying Adequate Warnings Directly to the Patient
The most common proposal to convey adequate warnings directly from manufacturer to patient is through the Patient Package Insert (pPI).63 PPIs are leaflets directly distributed with prescription drugs to the patient that describe in lay language the drug's indications, directions for use, and side effects. The FDA currently only requires Walsh et aL, supra note 52, at 823 (arguing that "imposing liability ror inadequnte patient warnings could adversely affect the availability and affordabllity o[ socially beneficial medicines").
61 See Terry, supra note 18, at 346 (notiDg that manufacturers who use web marketing circumvent learned intermediary).
. 61 See Restatement ('Ibird) of Torts: Products Liability § 6(d) (1997). The drafting committee took pains to note that "direct warnings and instructions to patients are warranted for drugs that are dispensed or administered to patients without the personal intervention or evaluation of a health-care provider." Id. at § 6 cmL e; see also Reyes, 498 F.2d at 1276 ("rrJhe manufacturer of a prescription drug who knows or has reason to know that it will not be dispensed as such a drug must provide the consumer \vith adequate wormation so that he can balance the risks and benefits of a given medication himselL").
63 See Plant, supra note SO, at 1032-38 (describing development of patient package inserts (PP1s»; Schwartz, supra note 51, at 847 (notiDg that courts should consider requiring PPIs for advertised drugs); McGarey, supra note 53, at 14849 (indicating that manufacturers should be obligated statutorily to include PPIs \vith their drugs); Paytasb, supra note 51, at 1368 (proposing FDA-mandated program of PPIs).
that PPIs be distributed with a small group of medications, including oral contraceptives,64 estrogens,6S progestational drug products,66 and certain asthma inhalers,67 due to the high degree of patient involve .. ment in the decision whether to use such medications, together with the potential for severe complications. 68 In 1995, the FDA proposed a rule requiring drug manufacturers to include "useful" patient informa .. tion with seventy-five percent of new prescriptions by 2000 and ninety-five percent by 2006. 69 Since adequate patient information for pharmaceuticals is currently produced for a limited number of medications, and indeed, extensive patient information has even been incorporated into prescription drug advertisements,7° PPIs seem at first glance to be an adequate solution to satisfying a manufacturer's duty to warn.
An Incomplete Solution
Advocates of mandatory PPIs, however, continue to envision them only as an adjunct form of patient information, secondary to the counseling provided by physicians. 71 This reluctance to embrace PPls as a primary source of drug information stems from two main concerns. First, as a result of the unique distribution system for prescription drugs, physicians are in a much better position to communicate directly with patients than are manufacturers. Second, the exacting judicial standard to which PPIs are subjected results in little actual protection from failure-to-warn liability.
a. Prescription Drug Distribution. As a result of the distinctive distribution system for prescription medications, pharmaceutical manufacturers rarely have an opportunity to communicate directly with the end users of their products. Approximately eighty percent of all branded prescription products are sold through drug wholesalers. 72 These wholesalers resell the medication to retail pharmacies and hospitals. 73 The medication arrives in bulk at the pharmacies where pharmacists repackage it into smaller quantities, dispense it to the patient as directed by a physician's prescription, and provide counseling. 74 Therefore, any mandatory PPI program still ultimately forces manufacturers to rely on physicians and pharmacists to distribute the warnings. 7S Furthermore, because manufacturers have little information on the individual characteristics of a specific patient using their medication or on the disease state the patient is trying to treat with their medication, PPIs must list comprehensively all possible adverse effects for all possible patients and treatment scenarios. Since medications have multiple indications and side effects that can vary based on the dose that is prescribed or even \vith the patient's race or gender, and contraindications can differ depending on the patient's concomitant drug therapy and other disease states, physicians and pharmacists have important roles in individualizing drug warningS. 76 73 See Szeinbach, supra note 72, at 321 (listing major customers of wholesalers). 74 See Kathleen A. Johnson, Emerging Roles for Pharmacists, in PhanDacy and the U.S. Health care System, supra note 72, at 217, 235 (noting that dispensing, labeling, and counseling are primary components of pharmacy practice). The role of pbarm3cists. however, is also expanding to encompass "pharmaceutical care." See id. at 226-34 (describing "pharmaCeutical care" as emphasizing consultation over dispensing medications).
75 See Plant, supra note SO, at 1075. 76 See Noah, supra note 51, at 175 (stating that physicians are best equipped 10 l3i1or discussion of drug therapy to needs of individual patients); Paytasb, supra note 51, at 1366 (discussing ability of physician to taBor warning to patient's individual needs, circumstances, and cognitive abilities).
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[Vol. 75:1452 tion. 77 Thus, within the conventional drug distribution system, the health care professional, with or without a mandatory PPI program, remains optimally situated to provide the best quality information most efficiently to the patient.
b. An Exacting Legal Standard. In cases that find an exception to the learned intermediary rule, manufacturer-provided warnings are scrutinized under rigorous failure-to-warn standards. 7s In applying this analysis, courts begin by assuming that all risks, no matter how remote, merit a warning directed to the consumer. 79 For example, in Davis v. Wyeth Laboratories, Inc.,80 the plaintiff had less than a one in a million chance of contracting polio from the manufacturer's vaccine. Sl Nevertheless, the court held that failing to warn of this risk rendered the vaccine unreasonably dangerous. 82 such as the brain."88 Still, the court upheld the jury's determination that "the absence of a reference to 'stroke' in the warning unduly minimized the warning's impact or failed to make the nature of the risk reasonably comprehensible to the average consumer."89 Third, courts often will ease the plaintiff's usual burden of proving causation in failure-to-warn cases. 90 In typical failure-to-warn cases, once the plaintiff has established the manufacturer's duty to provide a warning, she then must prove that she "would have read, understood, and heeded an adequate warning, thus avoiding the injury in question."91 In a prescription drug scenario, however, some courts establish a rebuttable presumption in favor of the plaintiff that if she had received the warning, she would not have used the product. 92 84 See Jacobs, supra note 79. at 162 ("For warnings claims. almost all courts have adopted one of two approaches to causation, either of which makes it relatively easy for plaintiffs to satisfy their burden of prooL ttl; Plant, supra note SO. at 1049 (writing that wben courts require drug manufacturers to warn patient directly, they bave been "deferentinl to plaintiffs in establishing the cause-in-fact element tt ). 91 Jacobs, supra note 79. at 161. 92 See, e.g., Stanback v. Parke, Davis & Co.. 6S1 F.2d 642, 646 n.S (4th Cit. 1931) (SlIlting that although manufacturer did not have duty to warn ultimate coDSumer, plaintiH "would be entitled to the presumption that a warning, had it been given. would have been heeded"); Reyes v. Wyeth Lab., 498 F.2d 1265, 1281 (5th Or. 1974) ("Where a consumer, whose iojuxy the manufacturer should have reasonably foreseen, is injured by a product sold without a required warning. a rebuttable presumption will arise that the consumer would have read any warning provided by the manufacturer, and acted so as to minimize Even those courts that have not granted such a presumption have employed a subjective standard for establishing causation, allowing the plaintiff to testify as to whether she would have heeded an adequate waming. 93 Critics complain that applying such demanding standards to prescription drugs overdeters prescription drug manufacturers, thereby reducing the availability of medication. 94 Indeed, under these stanthe risks."); Seley v. G.D. Searle & Co., 423 N.E.2d 831, 838 (Ohio 1981) ("(\V)here no warning is given, or where an inadequate warning is given, a rebuttable presumption arises, beneficial to the plaintiff, that the failure to adequately warn was a proximate cause of the plaintiff's ingestion of the drug."); Jacobs, supra note 79, at 162 ("[A rebuttable presumption] frees plaintiffs from the obligation to prove either their general inclination to read and obey product warnings or the fact that they have actually done so in the particular case. "); Plant, supra note 50, at 1050 ("In some cases when courts have held that the mllnUfacturer had a duty to warn the patient directly, the patient is aided by a rebuttable presumption: if he would have received the warning, he would not have used the product."); Schwartz, supra note 51, at 847 ("Some courts, recognizing the difficulty of proving causa· tion in warning cases, have created a rebuttable presumption of a causal Iinkllge in such cases."); cf. also Henderson & 1\verski, supra note 79, at 278 ("Many courts have held that when the defendant fails to provide an adequate warning, it is presumed that such a warning would have been read and heeded by the user had it been given.").
93 See MacDonald, 475 N.E.2d at 72 (stating that:
The jury were free, however, to credit MacDonald's testimony that she would not have used the pills had she been advised of the danger of 'stroke,' and to infer that an explicit reference to the risk of stroke might tip the balance in a reasonable person's choice of a contraceptive method.); Jacobs, supra note 79, at 162-63 (stating that courts that do not use rebuttable presumption "employ a subjective standard for establishing causation, allowing a plaintiff to testifyafter the fact of his injury, of course-as to whether he would have read and heeded an adequate warning had the defendant placed one on its product"); Plant Various alternatives to traditional fallure-to-warn analysis, such as a regulatory compliance defense, have been proposed_ See Richard C. Ausness, The Case for a "Strong" Regulatory Compliance Defense, 5S Md. L Rev. 1210, 1213 (1996) ("[A] strong regulatory compliance defense would .•• more than offset any negative effects that the defense might have on product safety and victim compensation."); Green, supra note 60, at 508 (writing that FDA regulatory compliance defense is not "unproblematic"): Henderson & 1\verski, supra note 79, at 270 ("Concepts such as risk foreseeability, risk-utIlity balancing, and darcls, manufacturers cannot realistically rely on the distribution of PPIs to fulfill their duty to warn in the context of Internet prescribing situations. When the consumer orders a medication from a prescribing-based site, it is dispensed with little physician interaction and shipped directly to the consumer. Because the PPI would become the patient's primary source of information without a health care professional readily available to interpret it, the usual worries that accompany PPIs are heightened. Thus, the PPI is a particularly unrealistic solution to bridge the warning gap so prevalent in online prescribing transactions. Moreover, the exacting liability standards used to analyze PPIS95 may deter manufacturers from relying on them at alt, necessarily precluding them from selling medications online unless other realistic direct-warning systems can be designed. In sum, tremendous concerns abound regarding both patient safety and the ability of drug manufacturers to insulate themselves sufficiently from liability, threatening the continuing viability of Internet prescribing and distribution.
The End of Internet Prescribing?
A well-run prescribing based site-operating within the contours of healthy physician-patient relationsbips-could offer certain segments of the population distinct practical advantages over brick and mortar doctors' offices and pharmacies. These advantages include unparalleled access to health care providers both nationwide and worldwide, the convenience of around-the-clock availability, increased privacy, and lower costs. 96 Additionally, the tremendous autonomy proximate causation are so devoid of content in the failure·ta-warn context that they cannot hope to test the bona fides of the plaintifPs claim. H); Peter Huber. Safety and the Second Best The Hazards of Public Risk Management in the Courts, 8S Colum. L. Rev. 277,335 (1985) ("Requiring-or at least strongly encouraging-the courts to respect the comparative risk choices made by competent, expert agencies would inject a first. small measure of rationality into a judicial regulatory system that currently runs quite v.ild. ")i Jacobs, supra note 79, at 177 ("Because the content-based approach to warnings law has failed, courts need to replace their minute inquiries into the details of risk and adequacy with a method of analysis that focuses on the procedures used by the manufacturer prior to the adoption and publication of its warning inCormation.")i Plant, supra note 50. at 1010 ("Principles should be adapted from the informed consent context to modify the obligations of pharmaceutical manufacturers so as to accommodate the unique nature of prescription drugs and medical devices."); Teresa Moran Schwartz, '!be Role of Federal Safety Regulations in Products Liability Actions, 41 Vande L. Rev. 1121, 1168 (1988) (arguing that "federal regulatory standards should Dot be treated as conclusively or presumptively adequate measures of safety under the common law"): VISCUSi et aL, supra, at 1439 (Slating that "tort liability should be limited through federallegistation"). The appropriate state of failure-ta-warn doctrine is beyond the scope of this Note; the risk of pOlentilllliability is the emphasis here, not how that liability will be, or should be, determined.
9S See supra DOtes 78-93 and accompanyiDg texL 96 See Hubbard 'Iestimony, supra Dote 45 (detailing the "mIlDY" bencfilS of prescription drug sales over the Internet); Senate Testimony, supra note 28 (noting that benefilS include the Internet provides patients can spur them to learn more about their medical conditions and history as well as to research their medications more thoroughly.97 More generally, the lessons learned from developing effective prescribing-based sites can help harness the Internet as a tool to streamline the massive information exchanges between physiaccess to drugs for the disabled or otherwise home-bound, for whom a trip to the pharmacy can be difficult; the convenience of shopping 24 hours a day; an almost unlimited number of products for customers; and privacy for those who don't want to discuss their medical condition in a public place); Drugstores on the Net, supra note 26, at 96 (statement of Janet Woodcock) (illegitimate prescription drug sales on the Internet can provide tremendous benefits to consumers."); American Med. Ass'n, Guidelines for Medical Practice Through the Internet, Resolution 832 (1999) <http://www.ama-assn.org!meetings/publiclannuaI99/reports/onsite/rtflh832.rtf> (stating that Internet medicine may be used "to reduce cost and improve access to health care delivery by preventing unnecessary patient travel"); Barbara J. 'lYler, Cyberdoctors: The Vlt1ual Housecall-The Actual Practice of Medicine on the Internet Is Here; Is It n Telemedical Accident Waiting to Happen?, 31 Ind. L. Rev. 259, 278 (1998) (U[P]roblems of unequal treatment of rural and urban patients can be dealt with using telemedicine as n conduit to deliver these services."); Ellen Almer, Online Therapy: An Arm's-Length Approach, N.Y. TlIDes, Apr. 22, 2000, at Al (noting that:
Some experts on mental health agree that online counseling, through e-mail, real-time e-mail exchange, and eventually video conferencing, is one of the most prOmising developments of the maturing Internet because it opens up new treatment options to people in remote areas, the disabled and those who feel too stigmatized to seek treatment for mental illnesses.). Such advantages might be particularly beneficial to the estimated 38.5 million Americans without health insurance and the estimated 43 he Internet hosts a large number of high-quality medical resources and poses seemingly endless opportunities to inform, teach, and connect professionals and patients alike."); 'lYler, supra note 96, at 269 ("The necessity for information for one's diagnosis or medical options has never been more obvious than now when consumers are faced with government and medicare funding cutbacks, hospital closings, waiting lists for surgical procedures, and doctors' and nurses' strikes."): David J. Morrow, Health Care Consumers Can Expect Change, and a Shock or 'lWo, N.Y. Tnnes, Dec. 20, 1999, at C6 ("One of the biggest changes during the next 10 to 20 years is expected to be the increasing role of tbe patient in choosing his or her treatment. Instead of relying only on their doctors' advice, consumers will also use medical information from the Internet and prescription-drug ad
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campugDS .. cians, insurers, pharmacies, and manufacturers now conducted on reams of paper forms. 98 The AMA also has identified at least three situations in which Internet prescribing may be used for legitimate electronic prescribing purposes.!19 For instance, after a physician examines a patient, she could enter a prescription order online for that patient and transmit it online to the pharmacy.lOO Alternately, if a patient has been and remains under the care of a physician, and has been seen in person by the physician in the recent past, the patient could contact electronically the physician when no refills remain on a previous prescription, and the physician could authorize the renewal online to the pha.rmacy.10l Fmally, the AMA notes that it may be appropriate for a physician to consult a patient online and issue that patient a new prescription pursuant to that online consultation if the physician has an ongoing relationship with the patient, has the patient's medical history and physical information available at the time of the consultation, and has seen the patient in the recent past. In this limited situation, new prescriptions for particular medications legitimately may be transmitted online to the pharmacy without an additional office visit.1 02 In light of these potential advantages, the AMA has stated that "[c]are must be taken to protect and even enhance legitimate electronic prescribing and dispensing practices." 103 Therefore, it is important that prescribing-based sites are not abandoned merely be-cause of the inability of our current regulatory system to police the safety of these transactions. 104 Only by improving prescribing-based sites and forcing them to operate responsibly, either by expanding the involvement of a doctor with the online transaction or by increasing the quality of the patient information provided, can their vast potential be realized. 1os Unfortunately, it is doubtful whether legislative or administrative mandates effectively could compel these websites, notorious for their ability to evade regulation, to reform their prescribing methods. 106 Furthermore, given the rapid pace of change within the Internet, such regulations likely will be obsolete before they are promulgated. t07 Finally, any proposed solution must ensure that both domestic and foreign websites will act to increase the safety of their transactions.
III ENHANCING THE SAFETY OF ONLINE PRESCRIBING:
A PROPOSAL This Note proposes that pharmaceutical manufacturers themselves are optimally situated to improve the operation of prescribingbased sites. Frrst, manufacturers can utilize the capabilities of the Internet to create comprehensive patient information systems that convey adequate warnings directly to the online patient. Scrutinizing patient information systems under a traditional failure-to-warn liability framework would increase effectively the quality of patient care provided by web sites without imposing an absolute ban on online prescribing. Second, to ensure that warnings will be distributed by websites regardless of where in the world they are based, the manufacturers, and not the government, must obligate websites to implement these systems. By balancing manufacturers' commercial in- 104 See Cohen, supra note 27, at 1 ("'The regulatory system for drugs was created at a time when the Internet was not envisioned.'" (quoting William Hubbard, deputy associate commissioner of FDA». See generally Bendavid, supra note 25 (arguing that current regulatory scheme is largely outdated).
lOS See Spielberg, supra note 98, at 1358 ("[B]lectronic communication, as a novel technology, is neither inherently unethical nor readily acceptable for medical practice. Rather, the emergence of electronic communication launches a reexamination of the necessary values for good communication in the patient-physician relationship."); Terry, supra note 18, at 350 (describing various ''new manifestations of cybermedicine"); 'lYler, supra note 96, at 283 ("Telemedicine could result in revolutionary changes in our health care delivery system. tI): Morrow, supra note 97 ("Health experts are confident that drugs win routinely be bought through the Internet, including treatments for serious conditions.").
106 See supra notes 22-37 and accompanying text. 107 See Green. supra note 26, at 368 (arguing that regulating Internet is "unlikely to be successful given that rapid technological advances can render such regulations obsolete by the time they are published").
terests in online prescribing, the practical advantages to consumers of online prescribing, and the health and safety concerns of patients, this proposal provides manufacturers with an economically viable way to enhance the safety of online prescribing.
A. Conveying Adequate Warnings Directly to the Patient: Revisited
The Internet can be used to create comprehensive patient information systems that improve the quality of the warnings conveyed to the online patient. Analyzing comprehensive patient information systems under traditional faiIure-to-warn liability, and indeed, even under the learned intermediary rule, will encourage safer forms of Internet prescribing. This Section suggests two approaches to satisfying manufacturers' duty to warn: enhancing the online physician-patient relationship or distributing Individualized Patient Reports (IPRs).
Enhancing the Online Physician-Patient Relationship: Extending the Learned Intermediary Rule
Increasing the amount of physician interaction given to the patient on each transaction is one way of enhancing the quality of patient information provided in the Internet prescribing conteh1.
Instead of merely presenting a prospective patient with an online questionnaire, for example, a website could implement an instant messaging system to allow the patient and a physician to interact with each other in real time. lOS Such an information exchange, albeit virtual, would resemble more closely a face-to-face examination in a physician's office than the typical online questionnaire. The physician would be able to ask all of her questions in real time and immediately receive the patient's answers, much as if they were speaking by telephone. If a court is convinced that the online information excbange is comprehensive enough to constitute a true physician-patient relationship and that the drug is dispensed according to an individualized medical judgment, then it should apply the learned intermediary rule. 109 By extending the learned intermediary doctrine to cover such situations, courts would provide manufacturers with an incentive to develop these higher quality online information exchanges. Expanding the learned intermediary rule to protect websites that implement enhanced online physician-patient relationships will encourage the development of Internet prescribing into a reliable source for prescription drug consumers.
While a virtual examination may not be the ideal traditional consultation originally envisioned by the learned intermediary rule, our modem health care system has eviscerated the traditional physicianpatient relationship.l1O Despite this, courts have continued to apply the learned intermediary rule, even in situations where the plaintiff argues that the physician-patient relationship was subpar. lll In Swayze v. McNeil Laboratories, inc.,112 the plaintiff's son died from an overdose of prescription anesthetic administered by a nurse anesthetiSt. 113 Though the nurse "testified that he alone determined the dosage,"114 the court found that since the physician "was present at all times ... he assumed the role of 'learned intermediary.' "115 Similarly, in Bacardi v. Holzman,116 the court applied the learned intermediary rule notwithstanding the plaintiff's claim that "he did not even know 109 If the current state of technology does not allow online information exchanges between pbysician and patient to rise to the level of a face-to-face consultation, courts should assign the duty to warn patients to the manufacturers. The manufacturers either will halt online sales or attempt to develop better ways to warn patients about their medications. For a thorough explanation of how a drug manufacturer should weigh liability risks. see Swayze v. McNeil Lab., Inc., 807 F.2d 464, 477·79 (5th Cir.1987) (Goldberg, J., dissenting). The learned intermediary rule "carrot," however, will remain, encouraging manufacturers who wish to sell their medications online to develop the technology that will someday enable online information exchanges to become and be deemed true physician'patient relationships. 110 For many of the reasons discussed in Part IT.A, courts are loath to disregard the learned intermediary rule even in situations where the quality of the physician-patient relationship is tenuous at best. l22 The continued availability of medication on the Internet, if within vigilantly controlled confines, should be afforded no less protection. Applying the learned intermediary rule to an online physician-patient relationship merely forces courts and manufacturers alike to examine carefully every aspect of the online relationship to ensure that it is similar in quality to a face-to-face consultation. l23 For guidance on how to apply this standard, courts should look to the AMA's minimum. standards of care. 124 If the court is satisfied that the online physician-patient relationship established by the prescribing-based site meets these criteria, it should extend failure-to-warn immunity to the manufacturer as long as it properly warned the online prescribing doctor. To conduct that analysis, a court should consider whether the doctor performed a thorough examination to determine whether an actual medical problem existed and to make a specific diagnosis. Second, there must be a dialogue between the physician and the patient to discuss treatment alternatives and to determine the best course of treatment. 'Third, the physician must effectively establish, or have ready access to, a reliable medical history. Fourth, the physician must provide adequate warning information to the patient. Finally, in certain cases, follow-up care will be necessary and the site will have to implement systems to make that possible. l2S The promise of a safe harbor from failure-to-warn liability will encourage a manufacturer to screen carefully the websites it sells its products to and to work with those websites to develop enhanced online physician-patient relationships. Certainly, there will be drugs that are so complex that no amount of online information exchange will adequately inform the patient of the risks involved.1 26 In such cases, it will be unreasonable for the manufacturer to have relied on an online physician to provide sufficient information for the specific drug; it sim~ ply should not be dispensed online. However, there are many other medications that could be prescribed and dispensed safely online. By balancing patient safety concerns with the advantages of Internet prescribing, and then instituting proper safeguards, a certain number of prescribing-based sites will be improved markedly, allowing the public to benefit from a new, safe model of drug distribution.
Leaving the Learned Intermediary Behind: A More Radical Proposal
As an alternative to bolstering the online physician-patient relationship, manufacturers might help the websites to distribute enhanced patient warnings that improve upon the traditional PPI. Such a model assumes that a physician would issue the prescription pursuant to an online questionnaire much as they do now, with minimal patient interaction; therefore, the shield of the learned intermediary rule would be inappropriate. The website, however, could provide the patient with Individualized Patient Reports (IPRs) to compensate for the reduced role of the prescribing physician. Since these IPRs will be examined closely under a traditional failure-to-warn liability framework, manufacturers will have strong incentives both to design optimal warnings and to consider carefully which types of medications to allow to be distributed in this way.
us See Drugstores on the Net, supra note 26, at 254 (statement of Herman I. Abromowitz).
126 Determining which medications could be appropriate for online prescribing would involve extensive therapeutic expertise; these reasonableness determinations probably will rely primarily on expert medical testimony. For a list of medications that one website has indicated as "inappropriate for online prescribing," see CyberDocs (visited July 8, 2000) <http://www.cyberdocs.comlnonprescribed.htm>. The list is primarily composed of controDed substances and is therefore not as weD thought out as a court would requIre. It is presented merely as an oversimplified example.
a. Individualized Patient Reports. (1) Comprehensive Patient
Information Reports: Under this proposal, manufacturers, in conjunction with the FDA, should first fashion comprehensive patient information reports for all of the medications to be sold on prescribingbased sites. This process could mimic the one already in place for the approval of the contents of a new drug's professional labeling, which requires manufacturers to submit to the FDA "a great deal of information about how the drug should be used, and safety-related information that includes contraindications, known adverse effects, and precautions in usage to avoid identified risks."127 For most approved prescription medications, this information is already found on the drug's package insert. The bulk of the work would be translating this wealth of complex medical information into language readily comprehendible by lay persons.
(2) The Online Questionnaire: Once the report is created, the manufacturers should implement a standard online questionnaire to be used by the prescribing-based sites. Any individual characteristics that physicians would find pertinent in making their prescribing decisions, such as sex, race, age, weight, allergies, and blood pressure should be included in the questionnaire. In addition, manufacturers should include other more esoteric characteristics that are material in light of the particular drug being prescribed. The questionnaire must also contain a section where the patient can indicate any other medications she currently is taking. Creating the ideal questionnaire will be much like creating the ideal report, in that it will involve a careful balance between brevity and detail. It should not be overly lengthy, lest it tempt patients to skip parts of it, but it must be detailed enough to allow for as much individualized profiling as possible.
(3) Individualization: By using the patient's answers to the online questionnaire, the website could create an individualized profile of the patient.128 The IPR then could customize itself to conform to the answers provided in the questionnaire, emphasizing the information that a patient fitting that profile would find most material. 129 For example, depending on whether the patient for which the drug was 127 Green, supra note 60, at 488; see also 21 c.F.R. § § . at 307 (noliag that "the order in which information is presented has a significant impact on its perception by the individU3l who must ultimately utilize the data to reach a decision"): Plut, supra note SO. at 1070 (arguing that manufacturers should be required to disclose information only when reasonable patient would find it material). intended was six years old or sixty years old, certain sections of the IPR would be highlighted, allowing the IPR to be comprehensive enough to encompass most known risks while minimizing "overwarning" the patient. The IPR could be shown to the patient online, preferably before the final order confirmation, so that the patient has a chance to review the pertinent risks of the medication before purchasing it. Once the medication is ordered, the IPR could be printed out and delivered with the patient's order. 130 IPRs could effectively provide consumers who order drugs from prescribing-based sites with adequate warning information reasonably tailored to their individual profile, thus improving IJpOn the tnd;tionnl PPI. Of course, this printed information will in many cases be inferior to information received through personally consulting with a physician or by speaking directly to a dispensing pharmacist. Yet, measured against the quality of patient information typically provided in the current weakened state of the physician-patient relationship, this will not always be the case.
b. A Case for Traditional Failure-to-Warn Liability.
If manufacturers choose to implement IPRs as described above, traditional failure-to-warn liability analysis would provide manufacturers with the proper incentives to police the Internet prescribing phenomenon, ensuring patient safety. In fact, it would be desirable if the exacting standards discussed in Part II.C.1.b prevented manufacturers from selling their medications to unscrupulous websites, distributing inadequate IPRs, or making particularly complex medications available to any website for online sale. Under this proposal, manufacturers will be free to partner with websites that they determine are reputable and create an extensive IPR program to accompany specific drugs they have deemed suitable for online sale. What the manufacturers must expect, however, is that the IPR thus created will be highly scrutinized under traditional failure-to-warn liability doctrine. The onus will be on the manufacturers to create the perfect IPR: readily understandable, sufficiently specific, and comprehensive. For certain medications this will be an impossible task, and liability concerns justifiably will prevent those medications from being sold online. Liability concerns will also deter manufacturers from selling their products to certain websites unable to implement an IPR program adequately. Likewise, 130 Additionally. the printout could include a toll·free phone number that patients could use to contact a health care professional with any additional questions tbey might have. Such a help center could be maintained by the manufacturer as part of their obligation to provide the PPIs and could serve as the final opportunity for the patients to receive highly individualized information about their medication.
if these IPRs fail to improve upon traditional PPIs to any significant degree, this liability standard will restrict their use, thereby precluding manufacturers from relying on this method of disseminating warnings to patients to fulfill their duty to warn.
Admittedly, a proposal to rely on IPRs as the sole source of drug information undoubtedly will encounter tremendous resistance from the medical community. In the absence of an extensive physician-patient relationship, creating IPRs that are sufficiently specific, yet thorough enough to be the patient's primary information source, will be extremely difficult. At its most conservative, this proposal couldand probably should-be used as an adjunct to the enhanced online physician-patient relationship described above. At its most ex1reme, such a proposal could force the reclassification of a particular class of medications to "quasi-prescription"; that is, medications that, based on their side-effect profiles, can be dispensed safely with a minimal amount of physician involvement and an adequate amount of patient information. 131 The possible weighing of the advantages and disadvantages that would be associated with the creation of a class of "quasi-prescription" medications, on the basis of either increased access or decreased cost, can only be debated once a feasible system for their distribution has been enabled. Regardless of whether a new class of "quasi-prescription" drugs ever arises, to the ex1ent that this proposal improves upon the quality of traditional PPIs, it undoubtedly can be implemented within our current scheme of drug distribution.
B. Distributing Adequate Risk Information in Internet Prescribing Situations
Pharmaceutical manufacturers are best situated to make certain that adequate risk information will be provided by websites that distribute drugs and thus contractually should obligate websites to implement the proposals discussed in Part m.A. As outlined in Part It it is unlikely that the government will be able to require all these sites, many of which are based in foreign countries, to distribute adequate patient warnings. The only common party to all of the sites around the world is the manufacturer, the source of all the medication sold on these sites, whether they are based in Boston or Bali. Since manufacturers are held to be experts on how their products are distributed,132 131 Possible candidates may include prescription antihistamines suth as Clmtin or Al· legra. These medications have a low incidence of side effects and are aVDilable \\ithout a prescription in Canada. The side effect information required in an adequate patient warn· ing may be too complex for traditional over-the-counter labeliDg. but might be conveyed adequately in the manner proposed here. "each of its affected direct accounts" about possible drug recaIls. 135 Also, since the websites maintain direct contact with the patient, forcing them to distribute risk information through these contractual arrangements alleviates many of the logistical difficulties previously mentioned.136 Therefore, as a precondition to selling their medications to a pharmacy or wholesaler that engages in Internet prescribing, manufacturers contractually should obligate purchasers to implement effective patient information systems. 137
Contractual Assignment of a Pharmaceutical Manufacturer's Duty to Warn
. Once a manufacturer creates a comprehensive patient information system, it then must obligate the websites to implement it effectively. The leading case permitting a pharmaceutical manufacturer to assign its duty to warn contractually is Mazur v. ~ferck & CO. 13S In Mazur, the Philadelphia health department purchased Merck's MMR IT vaccine for the city's immunization program.13 9 Merck sold the medication pursuant to a contractual provision obligating the United States Centers for Disease Control (CDC) to ensure that the vaccine would be administered (1) on the basis of an individualized medical judgment by a physician, or (2) \vith meaningful warnings, provided directly to the patient. l40 Pursuant to the latter provision, the CDC created an "Important Information Statement" informing patients in lay language of the risks of the vaccine, and obligated the Philadelphia health department to distribute the statement to vaccinees, or their parents or guardians. 141 Applying the mass immunization exception to the learned intermediary rule,142 the court first held that Merck did indeed have an obligation to warn users directly of the risks of its vaccine. 143 Applying the Restatement (Second) of Torts § 388, however, the court also held that "a vaccine manufacturer may satisfy its duty to warn in the mass immunization context by obligating the CDC to warn users directly if it informs that agency of the facts which make its vaccine dangerous and reasonably relies on it to communicate such information to users in lay terms."144 The court first concluded that the package circular distributed with the MMR II vaccine was adequate to inform the CDC of the dangers associated with the vaccine. 145 The court also noted that Merck had researched the CDC carefully before agreeing to sell its vaccine and continually monitored the CDC's dissemination efforts.146 Finally, "[g]iven the resources and funding available to the CDC, as well as its expertise in immunology and public vaccination," the court held that Merck reasonably relied on the CDC to warn users of its vaccine directly.147
In order to ensure that prescribing-based sites will distribute adequate warnings, pharmaceutical manufacturers should draft contracts similar to Merck's contract with the CDC in Mazur. That is, manufacturers either coUld obligate the site to dispense their drug only after an individualized medical decision by an online physician, or require them to distribute meaningful patient warnings (Le., IPRs), thus ade-141 See id. This arrangement is analogous to the proposal outlined supra Part III.A.2. 142 See supra note 58. 143 See Mazur, 964 F.2d at 1369. 144 Id. at 1365. Under Pennsylvania law, the court noted that an unavoidably unsafe product under comment k is not considered under § 402A but under § 388, which requires the manufacturers to meet a standard of reasonableness, and not one of strict liability. See id. at 1364-66. 145 See id. at 1367. 146 See id. at 1368. 147 Id. Admittedly, the heavily case-specific nature of the "reasonableness" test may lead courts to reach varying results. In Allison v. Merck & Co., 878 P.2d 948 (Nev. 1994), the plaintiff was injured in a similar situation by the same MMR II vaccine. See id. at 951-52. Even though Merck contractually had obligated the CDC to warn the vDccinees, the court found that the CDC had "admitted biases against 'discourag[ing] the use of vaccines.'" Id. at 958 n.17 (alteration in original). Accordingly. the court reasoned that "a jury could conclude that Merck knew or had reason to know that the CDC was not going to provide the truth about Merck's product and did not, in fact, give proper warning." Id. Therefore, "Merck fully realized how inadequate the warning really was." Id. In a dissenting opinion. Justice Young concluded that Merck reasonably relied on the CDC to formulate and distribute proper warnings for its vaccine. See id. at 968-69 (Young, J., dissenting).
However, the ambiguity inherent in any reasonableness test can also be its strength. Courts adjudicating Internet prescribing cases will confront ever evolving technology. A reasonableness test will be flexible enough to encompass the widely varying fact patterns that courts are sure to encounter. quately informing them of the pertinent dangers in the products. Mazur~s reasonableness test would encourage manufacturers to investigate these sites carefully, examining the site's credibility, the procedures that it would use to implement a patient information program, and the resources that the site mayor may not have in place to create a proper physician-patient relationship. It would not be reasonable for a manufacturer to enter into such contracts with every prescribingbased site, and the knowledge that dealing with an unscrupulous site may expose it to potential liability will discourage the manufacturer from dealing with such sites. A careful application of the },[aZlir test ensures that manufacturers maintain ultimate responsibility over the implementation of the warning system. 148 The reasonableness test also would limit the types of medications sold online, encouraging manufacturers to consider carefully whether it is reasonable for particular drugs to be distributed online. 149 Manufacturers would also have the duty to visit these sites often to monitor the effectiveness of their warning efforts and to refuse to sell their medications to any sites that are not complying with their contractual obligations.
Contractually obligating prescribing-based sites to distribute patient warnings is an efficient way to require these websites to improve their prescribing practices. By obligatirig certain prescribing-based sites to implement adequate patient s~eguards, some of the sites will become viable alternatives to the traditional drug distribution system. 148 Courts that have addressed the delegation of the duty to warn by a pharmaceutical . manufacturer emphasize that the manufacturer must maintain ultimate responsibility over the warning system it chooses to implement See Petty v. Though there are no large-scale studies available showing that telemedicine is as safe and effective as in·person consultations \vith a physician. II small study conducted by the Medical College of Georgia found no difference between the diagnoses pb)"Sicians made using a telecommunications link and those diagnoses they made in person. See '!Yler. supra Dote 96, at 279. For further discussion of telemedicine and possible medical malpractice liability, see generally Kearney, supra note 29. at 300-02; Spielberg. supra note 29. at 287-93.
[Vol. 75:1452 Those sites that refuse to, or cannot, adhere to these contractual guidelines will be cut off from their drug supply by the manufacturers and will wither away.
CONCLUSION
Internet prescribing has the potential to put millions of consumers at the risk of injury, presenting pharmaceutical manufacturers with a host of potential liability concerns. These concerns must be balanced against the tremendous commercial possibilities and practical advantages offered by Internet prescribing. At this early stage, with the full potential of the Internet far from realized, it would be inadvis~ able and unnecessary for the government to place wholesale restrictions on prescribing-based websites. Instead, failure-to-warn analysis can be used as a framework for drug manufacturers to improve the quality and safety of Internet prescribing. By encouraging the development of safer forms of Internet prescribing, instead of banning it entirely, the public can continue to benefit from the online health care revolution.
